Wealthcare Advisory Partners’s NovoCure NVCR Stock Holding History

Wealthcare Advisory Partners’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-487	Closed	-$64K	–	1404
2021 Q1	$64K	Buy	+487	New	+$77K	﹤0.01%	804
2020 Q2	–	Sell	-417	Closed	-$28K	–	1023
2020 Q1	$28K	Buy	417 +157	+60%	+$12.4K	﹤0.01%	635
2019 Q4	$22K	Hold	260	–	–	﹤0.01%	744
2019 Q3	$19K	Hold	260	–	–	﹤0.01%	763
2019 Q2	$16K	Hold	260	–	–	﹤0.01%	780
2019 Q1	$13K	Hold	260	–	–	﹤0.01%	759
2018 Q4	$9K	Hold	260	–	–	﹤0.01%	815
2018 Q3	$14K	Hold	260	–	–	﹤0.01%	762
2018 Q2	$8K	Buy	+260	New	+$7.23K	﹤0.01%	900

Other funds holding NVCR

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wealthcare Advisory Partners's NVCR Position: Q2 2021 in Review

Wealthcare Advisory Partners sold out of NovoCure (NVCR) in Q2 2021, closing a stake of 487 shares — an estimated $64K sold.

Wealthcare Advisory Partners first reported a position in NVCR in Q2 2018 and held it in 9 quarters. The position peaked at $64K in Q1 2021. 361 funds tracked by Wall St. Rank hold NVCR as of Q2 2021.

Wealthcare Advisory Partners reported no remaining NovoCure position as of Q2 2021 after selling out during the quarter.
Wealthcare Advisory Partners sold 487 NovoCure shares in Q2 2021, an estimated $64K.
Wealthcare Advisory Partners first reported a position in NovoCure in Q2 2018 and held it in 9 quarters.
Wealthcare Advisory Partners's NovoCure position peaked at $64K in Q1 2021.
361 funds tracked by Wall St. Rank held NovoCure as of Q2 2021.

Based on Wealthcare Advisory Partners's 13F filing for Q2 2021, filed 16 Aug 2021.